Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC
Voice
Description
Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education